Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis

Charles A. Sninsky,David Cort,Fergus Shanahan,Bernard J. Powers,John T. Sessions,Ronald E. Pruitt,Walter H. Jacobs,Simon K. Lo,Stephan R. Targan,James J. Cerda,Daniel E. Gremillion,William J. Snape,John Sabel,Horacio Jinich,James M. Swinehart,M. DeMicco

Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis

2020

Charles A. Sninsky
David Cort
Fergus Shanahan
Bernard J. Powers
John T. Sessions
Ronald E. Pruitt
Walter H. Jacobs
Simon K. Lo
Stephan R. Targan
James J. Cerda
Daniel E. Gremillion
William J. Snape
John Sabel
Horacio Jinich
James M. Swinehart
M. DeMicco

▪ Objective: To evaluate the efficacy and safety of a pH-sensitive, polymer-coated oral preparation of mesalamine in patients with mildly to moderately active ulcerative colitis. ▪ Design: A multic...

Keywords:

Internal medicine
in patient
Diabetes mellitus
Gastroenterology
Cardiology
Ulcerative colitis
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations